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Abstract Succinyl-CoA:3-ketoacid CoA transferase (SCOT)
deficiency is a rare inherited metabolic disorder of ketone
metabolism, characterized by ketoacidotic episodes and often
permanent ketosis. To date there are ∼20 disease-associated
alleles on the OXCT1 gene that encodes the mitochondrial
enzyme SCOT. SCOT catalyzes the first, rate-limiting step of
ketone body utilization in peripheral tissues, by transferring a
CoA moiety from succinyl-CoA to form acetoacetyl-CoA, for
entry into the tricarboxylic acid cycle for energy production.We
have determined the crystal structure of human SCOT, provid-
ing a molecular understanding of the reported mutations based
on their potential structural effects. An interactive version of
this manuscript (which may contain additional mutations
appended after acceptance of this manuscript) may be found
on the web address: http://www.thesgc.org/jimd/SCOT.
Abbreviations
SCOT Succinyl-CoA:3-ketoacid CoA transferase
OXCT1 3-oxoacid CoA transferase 1
Introduction
Ketone bodies (acetoacetate, 3-hydroxybutyrate, acetone),
predominantly produced in the liver, provide extrahepatic
organs such as heart and brain with energy when glucose
supply is limited (Sass 2012). Any enzyme malfunction in
ketone body utilization (ketolysis) could lead to a buildup of
unused ketone bodies and result in ketoacidosis. Succinyl-
CoA:3-ketoacid CoA transferase (SCOT; gene name
OXCT1; EC 2.8.3.5) catalyzes the first and rate-determining
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step of ketolysis (Fukao et al 2000; Kassovska-Bratinova et al
1996). SCOT is a member of the CoA transferase family I that
activates acetoacetate by transferring a CoA moiety from
succinyl-CoA to form acetoacetyl-CoA. Acetoacetyl-CoA is
further metabolized by acetoacetyl-CoA thiolase into two
acetyl-CoA molecules which enter the citric acid cycle for
energy production (Williamson et al 1971). SCOT is a mito-
chondrial enzyme expressed in all extrahepatic tissues, but
abundant in the heart, brain and kidney (Fukao et al 1997).
There exists also a testis-specific isoform SCOT-t (gene name
OXCT2), sharing 74 % amino acid identity with SCOT
(Tanaka et al 2002).
Mutations in the human OXCT1 gene on chromosome
location 5p13 result in the rare autosomal recessive deficiency
of SCOT (OMIM 245050) (Mitchell and Fukao 2001). SCOT-
deficient patients, often with neonatal onset, present with re-
current ketoacidosis episodes that could be life-threatening, but
with no symptoms between episodes (Niezen-Koning et al
1997). The number of reported cases is few, and symptoms,
whichmay vary among individuals, include vomiting, lethargy
and tachypnea, as well as unconsciousness caused by severe
ketoacidosis (Berry et al 2001; Sakazaki et al 1995;
Snyderman et al 1998). Permanent ketosis or ketonuria is a
characteristic symptom but may be absent in patients retaining
residual SCOT activity (Fukao et al 2010; Fukao et al 2011;
Fukao et al 2004). Approximately 30 affected probands were
reported to date and 24mutations identified (Table 1). Here we
report the crystal structure of human SCOT, and present an
interactive mapping of missense mutations to understand the
molecular basis of SCOT deficiency.
Table 1 Mutations reported for the human OXCT1 gene causing SCOT deficiency. Additional phenotype information can be found in the
supplementary text
# DNA change Exon Mutation site Mutated
residue
Protein change Conservation Reference
1a,c,d c.112C>Tb 2 Arg38 Cys p.R38C (Alkén 2008)
2c c.335T>Ab 4 Val112 Asp p.V112D Semi-Conserved (Alkén 2008)
3 c.398T>A 4 Val133 Glu p.V133E Semi-Conserved (Song et al 1998)
4 c.644C>T 6 Ala215 Val p.A215V Conserved (Fukao et al 2011)
5 c.656G>A 6 Gly219 Glu p.G219E Conserved (Fukao et al 2000)
6 c.661G>A 6 Val221 Met p.V221M Semi-Conserved (Fukao et al 2000)
7 c.677G>A 7 Ser226 Asn p.S226N Semi-Conserved (Fukao et al 2011)
8c c.785C>G 8 Pro262 Arg p.P262R Conserved Sass et al (unpublished)
9c c.802C>T 8 Arg268 Cys p.R268C Conserved Sass et al (unpublished)
10 c.803G>A 8 Arg268 His p.R268H Conserved (Fukao et al 2007)
11 c.971G>A 10 Gly324 Glu p.G324E Conserved (Fukao et al 2000)
12 c.980T>C 10 Leu327 Pro p.L327P Conserved (Fukao et al 2011)
13† c.1162A>Gb 12 Met388 Val p.M388V Conserved (Alkén 2008)
14 c.1210G>T 13 Val404 Phe p.V404F Conserved (Fukao et al 2011)
15 c.1213T>C 13 Ser405 Pro p.S405P Conserved (Fukao et al 2011)
16†‡ b 14 Leu429 Phe p.L429F Conserved (Alkén 2008)
17 c.1304C>A 14 Thr435 Asn p.T435N Conserved (Fukao et al 2010;
Fukao et al 2004)
18 c.1367G>T 15 Cys456 Phe p.C456F Conserved (Song et al 1998)
19 c.1402C>T 15 Arg468 Cys p.R468C Low-conserved (Fukao et al 2011)
Insertion, deletion, frameshift mutations
20 c.649C>T 6 Arg217 X p.R217X Semi-Conserved (Longo et al 2004)
21 c.817G>T 8 Glu273 X p.E273X Variable (Fukao et al 2011)
22 c.848C>G 9 Ser283 X p.S283X Conserved (Yamada et al 2007)
23 c.658-666dup 6 Asn220-Ile222 p.N220-I222 dup Conserved (Asn220),
Semi-conserved (Val221,Ile222)
(Fukao et al 2010)
24 c.1561T>Cb 6 X521R Arg Adding 20 AAs (Alkén 2008)
aThe R38C mutation resides in the N-terminus of the protein that is disordered and not modelled in the crystal structure
b DNA change in the R38C, V122D, M388V and X521R mutations are deduced from amino acid substitution. The DNA change in the L429F
mutation is not reported and cannot be deduced from amino acid substitution
c These mutations have not been confirmed as pathogenic by expression analysis
d R38C and L429F mutations coexisted in one mutant allele
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Experimental procedures
Expression, purification & crystallization
DNA fragment encoding the catalytic domain of human
SCOT (aa 40–520; GenBank entry 4557817) was subcloned
into pNIC-CTHF vector incorporating a C-terminal His6-
tag. The plasmid was transformed into BL21(DE3)-R3-
pRARE2, cultured in Terrific Broth at 37 °C, and induced
with 0.5 mM IPTG. Cells were homogenized in lysis buffer
(50 mM HEPES pH7.5, 500 mM NaCl, 5 % glycerol, 5 mM
imidazole, 1 mM PMSF, 0.5 mM TCEP), centrifuged to
remove cell debris, and the supernatant was purified by
Nickel affinity (HisTrap 1 ml GE/Amersham) and size ex-
clusion (HiLoad 16/60 Superdex S200) chromatography.
Purified protein was concentrated to 21 mg/ml and stored
in 10 mM HEPES pH7.5, 500 mM NaCl, 5 % (w/v) glyc-
erol and 0.5 mM TCEP at −80 °C. Crystals were grown by
vapour diffusion at 20 °C, in sitting drops mixing 100 nl
protein pre-incubated with 2 mM acetyl-CoA and 300 nl
reservoir solution containing 0.20 M sodium chloride, 0.1 M
Tris pH9.0 and 25 % (w/v) polyethylene glycol 3,350.
Crystals were cryo-protected in mother liquor containing
20 % (w/v) glycerol and flash-frozen in liquid nitrogen.
Fig. 1 Ribbon diagram of
human SCOT structure
illustrating the homodimeric
assembly. The two monomeric
subunits a and b are coloured
distinctively (blue and
magenta). The active site in
each subunit is indicated by the
Glu344 residue shown in
orange sticks
Fig. 2 Clustering of human
SCOT missense mutations,
displayed in the same colour
scheme as Fig. 1. The positions
of amino acid mutations are
indicated by small spheres and
numbered according to Table 1.
Mutations that affect the
monomeric fold or dimerization
interaction are coloured red and
yellow respectively
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Data collection & structure determination
Diffraction data to maximum resolution of 2.20 Å were
collected on beamline X10A at the Swiss Light Source,
and processed using the CCP4 Program suite (CCP4
1994). SCOT crystallized in the P21 space group with
four molecules in the asymmetric unit (Supplementary
Table 1). The structure of human SCOT was solved by
molecular replacement with PHASER (McCoy et al
2005), using the pig heart structure as search model
(PDB code 1M3E)(Bateman et al 2002). Initial automat-
ed model building was performed with ARP/wARP
(Perrakis et al 2001), followed by cycles of iterative
manual model building with COOT (Emsley and
Cowtan 2004) and REFMAC5 refinement (Murshudov
et al 1997). The refined model consists of protein resi-
dues 40–285 and 297–519. No electron density was
observed for part of the inter-domain linker (residues
286–296). No ligand density for acetyl-CoA was found
in the active site though it was added during crystalliza-
tion. Structure factors and coordinates were deposited in
the Protein Data Bank under the accession code 3DLX.
Results and discussion
We have determined the crystal structure of human SCOT
which exhibits a homodimer architecture containing two active
sites (Fig. 1). Each monomer consists of the amino-terminal
(N-; aa 40–272) and carboxy-terminal (C-; aa 298–510)
domains, connected by a linker region (aa 273–297). The N-
and C-domains share a common α/β structural fold for CoA
transferase family I members (Heider 2001), as previously seen
in the pig SCOTstructure (89% sequence identity)(Bateman et
al 2002). The active site of each monomer is situated at the
interface of the two domains, where a strictly conserved resi-
due Glu344 (Fig. 1, orange sticks) attacks the incoming
succinyl-CoA substrate and forms an enzyme-CoA thio-
ester intermediate, as an integral part of the catalytic
mechanism (Solomon and Jencks 1969). Residues in the
active site of human SCOT are also conserved in the
testis-specific isoform SCOT-t, suggesting it may have
enzymatic activity.
To date, three nonsense, two insertion and 19 missense
mutations leading to SCOT deficiency are known from litera-
ture or newly reported here (Table 1 and Supplementary text),
although six missense mutations have not been confirmed as
pathogenic mutations by expression analysis. There is a poly-
morphism c.173C>T (T58M) which retains full enzyme
activity (Song et al 1998). The three nonsense mutations
(R217X, E273X, S283X) are expected to cause premature
translation termination, resulting in truncated SCOT proteins
that lack completely the C-domain and hence abolish part of
the active site. Another mutation c.1561T>C at the termi-
nation codon results in X521R and adds 20 amino acids in
the C terminus of SCOT peptide (Alkén 2008). The mis-
sense mutations are broadly distributed between the N- and
C-domains of the protein, although two clusters of ‘muta-
tional hotspots’ can be observed (Fig. 2). One cluster is
close to the interface between two SCOT subunits in a
dimer. A duplication mutation (N220-I222dup) is also pres-
ent in this region (Fukao et al 2010). The other cluster is
located in secondary structure elements that make up the
active site and CoA-binding site of the enzyme.
The mapping of missense mutations onto the human
SCOT structure allows us to classify their potential struc-
tural consequences broadly into three types. In the first
type, amino acids tightly packed in the enzyme are substi-
tuted to bulkier and/or charged residues (Fig. 2 and Table 1,
#2–7,11,14,16,17). This likely results in severe steric and
electrostatic clashes in the local environment which in turn can
compromise severely the folding, architecture and stability of
the enzyme. These mutants often result in the more severe
phenotype (permanent acidosis), consistent with their much
diminished enzyme activity (Fukao et al 2000; Song et al
1998). The second type disrupts the integrity of a secondary
structure element, either by introducing a conformationally-
restrained residue (e.g. Pro, Gly) into an α-helix/β-strand
(Fig. 2 and Table 1, #12,15), or by removing such residues
from their critical involvement in a loop/turn segment (Fig. 2
and Table 1, #8). The third type involves the substitution of
arginine residues where their guanidinium side-chains are
involved in salt bridge formation. These charged interactions
contributed to stabilizing two neighbouring regions in 3D
space that are distant apart in the polypeptide sequence.
Substitution of arginine to a weakly positive-charged (Fig. 2
and Table 1, #10) or uncharged amino acid (Fig. 2 and Table 1,
#9,19) will abolish these salt bridges. Though retaining partial
enzyme activities, these mutant proteins are thermally less
stable compared to wild-type (Fukao et al 2007; Fukao et al
2011).
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